Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henner Knust

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Chimia|December 2, 2014
Adventures in drug-like chemistry space: from oxetanes to spiroazetidines and beyond!Mark Rogers-Evans, Henner Knust, Jean-Marc Plancher, et al.
Neuropharmacology|August 10, 2014
Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterizationPari Malherbe, Frédéric Knoflach, Anne Marcuz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2017
Preclinical Evaluation of <sup>18</sup>F-RO6958948, <sup>11</sup>C-RO6931643, and <sup>11</sup>C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer DiseaseMichael Honer, Luca Gobbi, Henner Knust, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2009
Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunctionBernd Buettelmann, Theresa M Ballard, Rodolfo Gasser, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2010
Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonistsHassen Ratni, Theresa M Ballard, Caterina Bissantz, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2009
The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunctionHenner Knust, Guido Achermann, Theresa Ballard, et al.
Psychopharmacology|October 22, 2008
RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptorsTheresa M Ballard, Frédéric Knoflach, Eric Prinssen, et al.
Journal of Medicinal Chemistry|August 24, 2012
Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease modelsAlexander Boländer, Daniel Kieser, Constantin Voss, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2009
Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist seriesGuido Achermann, Theresa M Ballard, Francesca Blasco, et al.
Scientific Reports|April 9, 2021
Basmisanil, a highly selective GABA<sub>A</sub>-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in manJoerg F Hipp, Frederic Knoflach, Robert Comley, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Chimia|December 2, 2014
Adventures in drug-like chemistry space: from oxetanes to spiroazetidines and beyond!Mark Rogers-Evans, Henner Knust, Jean-Marc Plancher, et al.
Neuropharmacology|August 10, 2014
Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterizationPari Malherbe, Frédéric Knoflach, Anne Marcuz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2017
Preclinical Evaluation of <sup>18</sup>F-RO6958948, <sup>11</sup>C-RO6931643, and <sup>11</sup>C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer DiseaseMichael Honer, Luca Gobbi, Henner Knust, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2009
Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunctionBernd Buettelmann, Theresa M Ballard, Rodolfo Gasser, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2010
Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonistsHassen Ratni, Theresa M Ballard, Caterina Bissantz, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2009
The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunctionHenner Knust, Guido Achermann, Theresa Ballard, et al.
Psychopharmacology|October 22, 2008
RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptorsTheresa M Ballard, Frédéric Knoflach, Eric Prinssen, et al.
Journal of Medicinal Chemistry|August 24, 2012
Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease modelsAlexander Boländer, Daniel Kieser, Constantin Voss, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2009
Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist seriesGuido Achermann, Theresa M Ballard, Francesca Blasco, et al.
Scientific Reports|April 9, 2021
Basmisanil, a highly selective GABA<sub>A</sub>-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in manJoerg F Hipp, Frederic Knoflach, Robert Comley, et al.
Pageof 3